Acella Loses Early Bid to Stop Class Status in Thyroid Drug Suit

Acella Pharmaceuticals LLC lost an early attempt to stave off class status in a consumer fraud lawsuit by thyroid patients who allege they overpaid for medication that didn’t contain the correct amount of active ingredient.

The company’s motion to strike class allegations was denied by the US District Court for the Northern District of Georgia, which said the plaintiffs adequately showed that their lawsuit can satisfy the requirements for class certification.

Plaintiffs Sue Faulkner and Nicola Tibbetts said they were economically harmed by purchasing the company’s ineffective “NP Thyroid” medication. They sought to represent a nationwide class of individuals who ...